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1. Introduction 
Dyslipidaemia is a major cardiovascular disease (CVD) risk factor that plays an important 
role in the progress of atherosclerosis, the underlying pathology of CVD. To keep lipids and 
lipoproteins levels within ideal range has been recommended by different national, regional, 
or global (2001; Graham et al. 2007; World Health Organization 2007) guidelines on the 
prevention and management of CVD. The prevalence and pattern of lipid disorder, 
however, differ between ethnicities and populations. 
As a component of the metabolic syndrome, dyslipidaemia often coexists with diabetes, 
the coronary heart disease (CHD) risk equivalent. An atherogenic lipid profiles consists of 
high triglycerides (TG) and small dense low-density lipoprotein cholesterol (LDL-C) and 
low high-density lipoprotein cholesterol (HDL-C). The importance of dyslipidaemia on 
risk of CVD in patients with diabetes has been extensively studied in numerous studies. 
Reduced HDL-C is well documented as an independent predictor of CVD events (Wilson 
et al. 1988; Cooney et al. 2009). In contrast, the role of TG as an independent risk factor for 
CVD is more controversial (Patel et al. 2004; Psaty et al. 2004; Barzi et al. 2005; Sarwar et 
al. 2007; Wang et al. 2007). Recently, the interest to use novel parameters such as total 
cholesterol (TC) to HDL ratio (TC/HDL-C), non-HDL-cholesterol (non-HDL-C), 
apolipoprotein B (apoB) and apolipoprotein A (apoA) to assess CVD risk has increased 
(Barzi et al. 2005; Pischon et al. 2005; Charlton-Menys et al. 2009). As a CVD risk predictor, 
the non-HDL-C has been considered to be superior to LDL-C (Cui et al. 2001; Schulze et 
al. 2004; Liu et al. 2005; Ridker et al. 2005). However, there are racial and geographic 
disparities in lipid profiles not only in general populations but also in individuals with 
different glucose categories. The Third Report of the National Cholesterol Education 
Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol 
in Adults (NCEP-ATP III) has recommended that certain factors be recognized when 
clinicians evaluate the lipid profile of different population groups (Adult Treatment Panel 
III 2002). Although management of lipids using NCEP-ATP III guidelines is applicable to 
all populations, unique aspects of risk factor profile call for special attention to certain 
features in different racial/ethnic groups. 
www.intechopen.com
 
Dyslipidemia - From Prevention to Treatment 
 
 
16
2. Ethnic differences in lipid profiles in general populations 
The prevalence of dyslipidaemia varies depending on the population studied, geographic 
location, socioeconomic development and the definition used (Wood et al. 1972; Mann et al. 
1988; Onat et al. 1992; Berrios et al. 1997; Ezenwaka et al. 2000; Foucan et al. 2000; Hanh et al. 
2001; Zaman et al. 2001; Azizi et al. 2003; Florez et al. 2005; Li et al. 2005; Hertz et al. 2006; Pang 
et al. 2006; Pongchaiyakul et al. 2006; Tekes-Manova et al. 2006; Zhao et al. 2007; Erem et al. 
2008; Steinhagen-Thiessen et al. 2008). Caucasians generally have higher mean TC 
concentrations than do populations of Asian or African origin (Fuentes et al. 2003; Tolonen et 
al. 2005). In general populations, the highest prevalence of hypercholesterolaemia (TC ≥ 
6.5mmol/l) has been seen in Malta (up to 50% in women) and the lowest in China (2.7% in 
men) in the World Health Orgnization (WHO) Inter-Health Programme (Berrios et al. 1997). 
However, inhabitants of the developing world now have had access to more fats in their diets 
and more sedentary lives; therefore the disease is becoming an increasing problem there. 
Ethnic differences in the risk of CVD and type 2 diabetes have consistently been identified, 
with the most studies comparing the risk between African-Americans and Whites. African-
Americans usually display a more favorable lipid profile compared with Whites, despite 
having the highest overall mortality rates from CVD. In general, African-American men 
have similar or lower LDL-C and TG but higher HDL-C levels compared with White men. 
There is evidence that the difference in HDL-C between African-American and White men 
may be due to a relatively lower hepatic lipase activity in African-Americans (Vega GL 
1998). The difference in TG may be related to increased activity of lipoprotein lipase in 
African-Americans (Sumner AE 2005). However, compared with Whites, Hispanics and 
Asians, African-Americans have less favorable levels of lipoprotein(a) (Lp[a]), which is 
structurally similar to LDL-C, with an additional disulfide linked glycoprotein termed 
ApoA. A number of studies have suggested that Lp(a) may be an important risk factor for 
CVD (Danesh J 2000; The Emerging Risk Factors C 2009).  
Compared to non-Hispanic Whites, Hispanics, specifically Mexican-Americans, have 
demonstrated lower HDL-C and higher TG levels (Sundquist J 1999). Data from the Dallas 
Heart Study and a smaller cross-sectional analysis of healthy individuals confirm that levels 
of Lp(a) are likely similar or even lower in Hispanics compared with Whites (Tsimikas S 
2009). Although Lp(a) levels have been associated with endothelial dysfunction in 
Hispanics, the relationship with coronary artery disease in this population is less clear.  
Asian Indians exhibit a higher prevalence of diabetes mellitus than Chinese and Malays 
(Tan et al. 1999). They also have higher serum TG concentrations and lower HDL-C 
concentrations than Chinese (Gupta M 2006). In the HeartSCORE and IndiaSCORE studies 
(Mulukutla et al. 2008) where lipids were measured with the same assay procedures for 
Asian Indians as for Whites and Blacks, Asian Indians had lowest TC and HDL-C and 
highest TG among all the ethnic groups studied. In another multi-ethnic study of the 1992 
Singapore National Health Survey (Tan et al. 1999), Asian Indians appeared to have lower 
HDL-C but higher TG levels compared with the Chinese group. Data in other racial/ethnic 
groups are somewhat limited. Mean total cholesterol and LDL-C levels are lower in 
American Indians compared with the US average, and levels of Lp(a) are reported to be 
lower than in Whites (Wang W 2002). East Asians tend to have lower LDL-C, HDL-C and 
TG as compared with non-Asians (Karthikeyan et al. 2009). East Asians have been reported 
to have low Lp(a) levels, whereas south Asians have higher mean Lp(a) levels (Geethanjali 
FS 2003; Berglund L 2004). 
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Globalization of the western lifestyle contribute to worldwide increases of adiposity and 
type 2 diabetes not only in adults but also in children and adolescents (Kelishadi et al. 2006; 
Schwandt et al. 2010). In the BIG Study comparing the prevalence of the metabolic 
syndrome components in children and adolescents of European, Asian and South-American 
ethnicities, Iranian and Brazilian youths had considerably higher prevalence of 
dyslipidaemia than German youths. The most remarkable ethnic difference detected in this 
study is the high prevalence of low HDL-C levels in Iranian children and adolescents (38%) 
compared with German youths (7%) (Schwandt et al. 2010). Future longitudinal studies 
should seek the clinical importance of these ethnic differences. 
3. Ethnic differences in lipid profiles in the state of hyperglycaemia 
3.1 Lipid disorder and CVD risk in individuals with hyperglycaemia 
Lipids and lipoproteins abnormalities are major metabolic disorders, commonly including 
elevated levels of TC, LDL-C, Lp(a) and TG and reduced levels of HDL-C. In patients with 
type 2 diabetes, a CHD equivalent (Juutilainen et al. 2005), it is most commonly 
characterized by elevated TG and reduced HDL-C (Goldberg, I. J. 2001; Krauss 2004; 
Kendall 2005). There is increasing evidence that the diabetic dyslipidaemia pattern is 
common not only in patients with overt diabetes (Barrett-Connor et al. 1982) but also in 
individuals with different glucose categories, i.e., impaired glucose tolerance (IGT) or 
impaired fasting glucose (IFG) (Meigs et al. 2002; Novoa et al. 2005; Chen et al. 2006; 
Pankow et al. 2007). These abnormalities can be present alone or in combination with other 
metabolic disorders. It is well known that the risk of morbidity and mortality from CVD is 
increased by two- to four-fold in diabetic patients compared with the general population 
(Kannel 1985; Morrish et al. 1991; Almdal et al. 2004). A number of studies have determined 
the association of dyslipidaemia with cardiovascular risk in people with hyperglycaemia, 
and most of them were conducted in patients with diabetes. There is a large body of 
evidence linking dyslipidaemia and cardiovascular risk in patients with diabetes against 
quite few negative reports (Vlajinac et al. 1992; Roselli della Rovere et al. 2003) on this issue. 
Cross-sectional studies have found positive associations of atherosclerotic vascular disease 
with TC (Ronnemaa et al. 1989; Jurado et al. 2009), LDL-C (Reckless et al. 1978; Agarwal et 
al. 2009; Jurado et al. 2009), non-HDL-C (Jurado et al. 2009), TG (Santen et al. 1972; 
Ronnemaa et al. 1989; Gomes et al. 2009), apoB (Ronnemaa et al. 1989) and Lp(a) (Mohan et 
al. 1998; Murakami et al. 1998; Smaoui et al. 2004), but inverse associations with HDL-C 
(Reckless et al. 1978; Ronnemaa et al. 1989; Smaoui et al. 2004; Grant and Meigs 2007; Gomes 
et al. 2009; Jurado et al. 2009) and apoA-I (Seviour et al. 1988; Ronnemaa et al. 1989).  
Prospective data have provided with further evidence. The UKPDS study (Turner et al. 
1998) has demonstrated that high LDL-C and low HDL-C are potentially modifiable risk 
factors for coronary artery disease (CAD) in patients with type 2 diabetes. TG, however, was 
not independently associated with CAD risk in this study, possibly because of its close 
inverse relationship with HDL-C. Results from the MRFIT (Stamler et al. 1993), in which 
356,499 nondiabetic and 5163 diabetic men without CHD at baseline were followed for 12 
years, indicated that serum cholesterol is an independent predictor of CHD mortality in men 
with diabetes. Rosengren et al. (Rosengren et al. 1989) showed similar results in a 
prospective study of 6897 middle aged diabetic men. Patients with TC > 7.3 mmol/l had a 
significantly higher incidence of CHD during the 7-year follow up than those with TC ≤ 5.5 
mmol/l (28.3% vs. 5.4%, p<0.05). Long term follow-up of the London cohort of the WHO 
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Multinational Study of Vascular Disease in Diabetics, consisting of 254 type 2 diabetic 
patients, has showed that TC was associated with incidence of MI (Morrish et al. 1991) and 
overall cardiovascular mortality (Morrish et al. 1990). The role of TC in predicting CHD was 
also confirmed in women patients with diabetes (Schulze et al. 2004). 
3.2 Ethnic difference in lipid profiles across glucose categories 
Although the ethnic variation in lipid patterns has been wided studied in general 
populations, the ethnic differences in lipid profiles given the same glucose levels have not 
been well investigated. This issue has been recently studied in the DECODE (Diabetes 
Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe) and DECODA 
(Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Asia) study, which 
consisted of 64 cohorts of mainly population-based from 24 countries and regions around 
the world, with about 84 000 Europeans and 84 207 Asians of Chinese, Japanese, Indians, 
Mongolians and Filipinos.  
In the collaborative analysis of seven ethnic groups of European and Asian populations 
(studies included see Appendix 1), considerable ethnic differences in lipid profiles were 
observed within each glucose category. Asian Indians exhibited an adverse lipid pattern 
consisting of low HDL-C and high TG across all glucose categories as compared with other 
ethnic groups. Reduced HDL-C is prevalent even in Asian Indians with desirable LDL-C 
levels regardless of the diabetic status. In addition, in most of the ethnic groups, individuals 
detected with undiagnosed diabetes had a worse lipid profile than did diagnosed cases. 
Age-, cohort- and BMI adjusted mean TC, LDL-C and TG increased while the mean HDL-C 
decreased with more pronounced glucose intolerance in most of the ethnic groups in 
individuals without a prior history of diabetes (Fig. 1 a-h). Subjects with undiagnosed 
diabetes, however, had a worse lipid profile than those with known disease. Within 
individuals with normoglycaemia, mean lipid and lipoprotein concentrations differed 
among the ethnic groups. The Europeans had highest TC (Fig. 1 a-b) and LDL-C (Fig. 1 c-d), 
while Qingdao Chinese had highest HDL-C levels among all ethnic groups (Fig. 1 e-f). In 
contrast, Asian Indians had the lowest TC (Fig. 1 a-b), LDL-C (Fig. 1 c-d) and HDL-C (Fig. 1 
e-f) but the highest TG (Fig. 1 g-h) among the ethnic groups (p <0.05 for all comparisons). 
These ethnic differences were consistently found in all glucose categories. 
The multivariate-adjusted odds ratio (95% CI) of having low HDL-C was significantly 
higher for Asian Indians, Mauritian Indians, Hong Kong Chinese and Southern Europeans 
but lower for Qingdao Chinese compared with Central & North (C&N) Europeans, across 
all glucose categories from normal to diabetes (Table 1). Asian Indians and Mauritian 
Indians tended to have higher but Southern Europeans lower odds ratios for having high-
TG compared with the reference group. Unlike that for HDL-C or TG, the odds ratio for 
having high LDL-C was consistently lower in all Asian ethnic groups compared with the 
reference, across most of the glucose categories.  
In the HeartSCORE and IndiaSCORE studies (Mulukutla et al. 2008) where lipids were 
measured with the same assay procedures for Asian Indians as for whites and blacks, Asian 
Indians had lowest TC and HDL-C and highest TG among all the ethnic groups studied. In 
another multi-ethnic study of the 1992 Singapore National Health Survey (Tan et al. 1999), 
Asian Indians appeared to have lower HDL-C but higher TG levels compared with Chinese. 
The findings of these previous studies are consistent with ours although glucose status was 
not controlled in the previous studies.  
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Similar to others (Harris and Eastman 2000; Hadaegh et al. 2008), we observed a worse lipid 
profile in individuals with undiagnosed diabetes than that of previously diagnosed patients 
in most of the ethnic groups, indicating individuals with undiagnosed diabetes are at 
increased CVD risk and need to be identified and treated early. On the other hand, 
glycaemic control is shown to be an important determinant of diabetic dyslipidaemia (Ismail 
et al. 2001). The better lipid profile in diagnosed diabetes as compared with undiagnosed 
diabetes might imply a benefit of lifestyle intervention or drug treatment targeting favorable 
metabolic profiles and hemoglobin A1c (HbA1c), a surrogate measure for average blood 
glucose. However, to what extent the levels of HbA1c have contributed to the differences is 
unknown due to the lack of information in the current study. In addition, the data on lipid-
lowering treatment is not available for most of the earlier studies conducted in the 1990s 
because the statins were not widely prescribed at that time. These deserve further 
investigation in future studies. 
In contrast to the lower HDL-C and higher TG profiles, Asian Indians had considerably 
lower TC and LDL-C concentrations than others. As shown in Table 2, 71% non-diabetic and 
57.6% diabetic Asian Indians had low LDL-C (< 3.0 mmol/l), while the corresponding 
figures were 19.2% and 24.6% (p < 0.01) for C&N Europeans and 46.6% and 38.8% (p < 0.01) 
for Qingdao Chinese. However, even within the low LDL-C category, there was still a 
higher proportion of Asian Indians having low HDL-C compared with others (Table 2). The 
results were confirmed in the same analysis conducted separately for men and women. 
There is a large body of evidence showing that diabetes is associated with a high prevalence 
of dyslipidaemia (Kannel 1985; Cowie et al. 1994; 1997; Jacobs et al. 2005; Bruckert et al. 
2007; Abdel-Aal et al. 2008; Ahmed et al. 2008; Okafor et al. 2008; Surana et al. 2008; Agarwal 
et al. 2009; Jurado et al. 2009; Papazafiropoulou et al. 2009; Roberto Robles et al. 2009; 
Temelkova-Kurktschiev et al. 2009; Zhang et al. 2009; Seyum et al. 2010). In the Framingham 
Heart Study (Kannel 1985), the prevalence of low HDL-C (21% vs. 12% in men and 25% vs. 
10% in women, respectively) and high TG levels (19% vs. 9% in men and 17% vs. 8% in 
women, respectively) in people with diabetes was almost twice as high as the prevalence in 
non-diabetic individuals. By contrast, TC and LDL-C levels did not differ from those of non-
diabetic counterparts. A similar pattern of lipid profiles was observed in the UK Prospective 
Diabetes Study (UKPDS) (1997). In this study, the plasma TG levels were substantially 
increased whereas HDL-C levels were markedly reduced in both men and women with 
diabetes compared with the non-diabetic controls. Higher prevalence has been reported in 
other studies. Data from a primary care-based 7692 patients with type 2 diabetes in the 
United States showed nearly half of the patients had low HDL-C (Grant and Meigs 2007). 
The figure was even worse in an urban Indian cohort of 5088 type 2 diabetes patients, with 
more than half having low HDL-C (52.3%) or high TG (57.9%) (Surana et al. 2008). In 
addition to the traditional lipid measurement, increased levels of apoB were also seen in 
patients with diabetes compared with non-diabetic individuals (Bangou-Bredent et al. 1999). 
It has been shown that the prevalence of lipid and/or glucose abnormality differs between 
ethnic groups. It is clear that certain ethnic groups have differences in lipid profiles in 
general. Elevated TG and reduced HDL-C, as the components of the metabolic syndrome 
and atherogenic dyslipidaemia, was seen more common in Asian Indians than in the Whites 
(Anand et al. 2000; Razak et al. 2005; Chandalia et al. 2008; Mulukutla et al. 2008), Chinese 
(Tan et al. 1999; Anand et al. 2000; Razak et al. 2005; The DECODA Study Group 2007; 
Karthikeyan et al. 2009), Japanese (The DECODA Study Group 2007; Karthikeyan et al. 
2009) or Africans (Mulukutla et al. 2008). In a nationally representative sample of seven 
www.intechopen.com
 
Dyslipidemia - From Prevention to Treatment 
 
 
20
ethnic groups in the UK (Zaninotto et al. 2007), the prevalence of low HDL-C was highest in 
south Asian groups such as Bangladeshi, Indian and Pakistani, followed by Chinese, Irish 
and those from the general population living in private households; In contrast, the lowest 
prevalence was seen in Black Caribbean. Similar finding was reported in another study 
where the comparison was made between non-South-Asians and South Asians (France et al. 
2003). In addition, African Americans have been reported to have less adverse lipid profiles 
than Whites or Hispanics despite the presence of diabetes (Werk et al. 1993; Cowie et al. 
1994; Sharma and Pavlik 2001). The causes of ethnic difference in levels of CVD risk factor 
are complex and may include genetic, environmental and cultural factors (Zaninotto et al. 
2007). However, little is known about such ethnic differences in lipid profiles at comparable 
glucose tolerance status. 
4. Causes of ethnic differences 
There are several factors that contribute to the development of dyslipidaemia (2001), 
including genetic factors (Cohen et al. 1994) and acquired factors (Chait and Brunzell 1990; 
Devroey et al. 2004; Ruixing et al. 2008) such as overweight and obesity (Denke et al. 1993; 
Denke et al. 1994; Brown et al. 2000), physical inactivity (Berg et al. 1997; Hardman 1999), 
cigarette smoking (Criqui et al. 1980; Cade and Margetts 1989; Umeda et al. 1998; Fisher et 
al. 2000; Wu et al. 2001; Maeda et al. 2003; Mammas et al. 2003; Venkatesan et al. 2006; Grant 
and Meigs 2007; Arslan et al. 2008; Batic-Mujanovic et al. 2008), high fat intake (Hennig et al. 
2001; Millen et al. 2002; Tanasescu et al. 2004), very high carbohydrate diets (> 60 percent of 
total energy) (McNamara and Howell 1992) and certain drugs (Lehtonen 1985; Fogari et al. 
1988; Roberts 1989; Middeke et al. 1990; Stone 1994) (such as beta-blockers, anabolic steroids, 
progestational agents, et al.). Excess alcohol intake is also documented as a risk factor 
(Umeda et al. 1998; Wu et al. 2001; Mammas et al. 2003) despite that moderate alcohol 
consumption may have a beneficial effect on improving HDL-C concentrations (De Oliveira 
et al. 2000; Shai et al. 2004). In addition, glycaemic control is an important determinant of 
dyslipidaemia in patients with diabetes (Ismail et al. 2001; Grant and Meigs 2007; Ahmed et 
al. 2008; Gatti et al. 2009). Among these acquired factors, overweight, obesity and physical 
inactivity appear to be most important (Denke et al. 1993; Denke et al. 1994; Berg et al. 1997; 
Hardman 1999; Brown et al. 2000). They are also the most important lifestyle variables that 
decrease insulin action and increase the risk of diabetes. 
The causes of ethnic difference in cardiovascular risk profile are complex. Possible 
contributors include genetic, environmental, psychosocial, cultural and unmeasured factors 
and many are not well clarified (Zaninotto et al. 2007). It is clear that the observed ethnic 
differences in lipid profiles cannot be explained by genetics alone and may be more 
indicative of lifestyle-related factors such as dietary pattern and physical activity (Ruixing et 
al. 2008; McNaughton et al. 2009; Sisson et al. 2009). To what extent is ethnic-specific lifestyle 
pattern associated with different lipid profiles deserves further investigation.  
4.1 Genetic factors 
An adverse lipid profile in Asian Indians has been reported to be associated with the greater 
susceptibility to insulin resistance (Tan et al. 1999; Anand et al. 2000; Bhalodkar et al. 2005; 
Palaniappan et al. 2007), and a higher percentage of body fat for the same BMI as compared 
with Whites (McKeigue et al. 1991), which may contribute to the high prevalence of CVD 
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(Kuller 2004) and diabetes (Ramachandran et al. 2008; Snehalatha and Ramachandran 2009) 
in this ethnic group. In addition, it may also reflect the genetic variation, for example, at the 
apoE locus (Tan et al. 2003) and an excess of other risk factors such as homocysteine, Lp(a) 
or dietary fat (France et al. 2003). 
4.2 Environmental factors 
As suggested by previous research, dietary factors may play a role in both lipid and insulin 
profiles, although these patterns may be mediated by body fat content (Ku CY 1998). Total 
fat (and saturated fat) intake has been shown to adversely affect total cholesterol 
concentrations in children, adolescents, and young adults (Post GB 1997). The difference in 
HDL-C concentrations between Qingdao and Hong Kong Chinese subgroups observed in 
the DECODA study cannot be simply explained by the difference in assay methods. It may 
largely attribute to the differences in dietary structure and preference, geographic and 
environmental factors. Shellfish and beer, for example, are commonly consumed all the year 
round in Qingdao. Nevertheless, whether other factors exist and contribute to the high 
HDL-C in Qingdao needs to be further investigated.  
Mexican Americans have been previously reported to have greater adiposity, higher TG 
levels and lower HDL-C levels than Anglos. The relationship between behavioral variables 
(caloric balance, cigarette and alcohol consumption, exercise, post-menopausal estrogen or 
oral contraceptive use) and lipid pattern has been investigated in the San Antonio Heart 
Study (1979–1982) (n=2,102) to explain the ethnic difference in lipids and lipoproteins. 
Adjustment for caloric balance (as reflected by body mass index) narrowed the ethnic 
difference in TG and HDL-C levels for both sexes, while adjustment for smoking widened 
the ethnic difference. For females, the ethnic difference was also decreased by adjustment 
for alcohol and estrogen use. However, adjustment for these behavioral variables did not 
completely eliminate the ethnic difference in lipids and lipoproteins in either sex. Increased 
central adiposity, more characteristic of Mexican Americans than Anglos, was positively 
associated with triglycerides and negatively associated with HDL-C levels, especially in 
females. Fat patterning made a more important contribution to the prediction of TG and 
HDL-C levels than did the other behavioral variables (except for caloric balance) and, in 
general, eliminated ethnic differences in lipids and lipoproteins (Steven H 1986). 
Epidemiologists should consider the use of a centrality index to distinguish different types 
of adiposity since it is easy and inexpensive to measure.  
5. Implications for management and prevention of dyslipidaemia 
Epidemiological investigations of human populations have revealed a robust relationship 
between lipids and CVD risk. Furthermore, the benefit of lipid-modifying strategy on 
cardiovascular events has been demonstrated from a large number of randomized clinical 
trials (Thavendiranathan et al. 2006; Mills et al. 2008), especially from those using 3-
hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (i.e., statins) (Goldberg, R. 
B. et al. 1998; Collins et al. 2003; Colhoun et al. 2004; Pyorala et al. 2004; Sever et al. 2005; 
Knopp et al. 2006; Shepherd et al. 2006). Intensive control of dyslipidaemia has been  
greatly emphasized in the prevention and management of CVD. Current guidelines from 
the National Cholesterol Education Program Adult Treatment Panel III (ATP III) (Adult 
Treatment Panel III 2002), the European Society of Cardiology (Graham et al. 2007) and  
the American Diabetes Association (American Diabetes Association 2009) consistently  
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Fig. 1. Age-, study cohort- and body mass index-adjusted mean lipid (geometric means for 
triglycerides) and lipoprotein concentrations and 95% CIs (vertical bars) in men (figure 1-a, 
c, e and g) and women (figure 1-b, d, f and h) by ethnicities and glucose categories.* p for 
trend < 0.05 within each glucose category. 
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Model adjusted for age, study cohort, body mass index, systolic blood pressure and smoking status. 
NFG, normal fasting glucose; NGT, normal glucose tolerance. a Reference group 
Table 1. Odds ratio (95% confidence interval) of having dyslipidaemia in relation to 
ethnicity by glucose categories. 
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 LDL-C < 3 mmol/l LDL-C ≥ 3 mmol/l 
 Normal 
HDL-C 
and 
normal 
TG, %
Low 
HDL-C a 
alone, % 
High 
TG b 
alone, 
% 
both,
% 
Normal 
HDL-C  
and 
normal 
TG, %
Low 
HDL-C a
alone, %
High  
TG b 
alone, 
% 
both, 
% 
Non-diabetic 
population 
 
Hong Kong 
Chinese 
29.3 9.9 1.6 4.2 32.1 12.9 3.7 6.2 
Qingdao Chinese 31.0 5.4 8.3 1.9 40.5 2.4 9.8  0.7  
Asian Indian 23.2 33.6 3.2 11.0 9.2 10.7 2.8  6.4 
Mauritian Indian 23.9 15.8 5.0 4.7 23.2 14.7 5.7 7.0 
Japanese 25.2 6.4 3.4 3.5 38.2 13.0 5.0 5.3 
Central & 
Northern 
European 
13.3 2.3 2.0 1.6 48.6 9.7 12.6 10.0 
Southern 
European 
14.2 4.3 1.1 2.1 45.5 15.1 7.8 10.0 
Diabetic 
population 
 
Hong Kong 
Chinese 
12.4 9.6 1.4 11.0 22.6 18.1 7.6 17.2 
Qingdao Chinese 21.1 3.5 11.1 3.1 37.9 2.7 19.1 1.5 
Asian Indian 12.8 17.4 6.0 21.4 8.1 12.4 7.2 14.7 
Mauritian Indian 12.4 8.6 6.4 10.2 21.2 15.5 10.2 15.5 
Japanese 14.3 6.0 7.1 5.1 34.3 11.6 12.2 9.4 
Central & 
Northern 
European 
10.5 2.8 4.9 6.4 30.4 9.3 16.4 19.4 
Southern 
European 
7.5 3.3 6.0 10.2 24.4 11.2 12.8 14.8 
a < 1.03 mmol/l in men and < 1.29 mmol/l in women 
b ≥ 1.70 mmol/l 
Table 2. Proportions (%) of individuals according to lipid levels stratified by diabetic status 
in each ethnic group. 
recommend that LDL-C should be the primary target of therapy not only in patients with 
CHD or diabetes but also in individuals with increased cardiovascular risk. In addition, 
non-HDL-C is set by ATP III as a secondary target of therapy and HDL-C and TG as 
potential target. The Current guideline, mainly based on the data of Whites, consistently 
recommend that LDL-C < 2.6 mmol/l should be the primary target of therapy in patients 
with diabetes. As shown in our study and others’ (Mulukutla et al. 2008; Karthikeyan et al. 
2009), the Asian Indian population had significantly lower TC and LDL-C than did Whites. 
The threshold of LDL-C for treatment target for Whites may be too high for Asian Indians. 
Further studies are warranted to verify this hypothesis and determine the threshold 
applicable to this ethnic group. 
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In contrast to LDL-C, HDL-C has been either dropped from (Graham et al. 2007) or set as a 
secondary (American Diabetes Association 2010) or tertiary (Expert Panel on Detection 2001) 
target in the major guidelines despite the strong evidence of reduced HDL-C as an 
independent risk factor for CVD (Boden 2000). This may change if more therapy choices 
developed to increase HDL-C levels and improve HDL function are shown to prevent CVD 
(Singh et al. 2007; Duffy and Rader 2009; Sorrentino et al. 2010) or reduce the residual 
cardiovascular risk (Fruchart J 2008). Most recently, the ARBITER 6-HALTS (Arterial 
Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and 
LDL Treatment Strategies in Atherosclerosis) trial has shown a significant improvement in 
serum HDL-C levels and regression of carotid intima-media thickness when ERN was 
conbined with statin therapy in patients with CHD or CHD equivalent (Taylor et al. 2009; 
Villines et al. 2010). Considering the high proportion of Asian Indians with adverse HDL-C 
levels, appropriate approaches to increasing HDL-C and/or improving HDL function may 
become an important treatment target in Asian Indians in order to reduce their excess CVD 
risks. 
6. Appendix 1 
 
Countries and 
studies 
Blood 
sample 
Total cholesterol High-density lipoprotein 
cholesterol 
Triglycerides 
China     
Hong Kong 
Cardiovascular 
DiseaseRisk 
Factor 
Prevalence 
Study 
Plasma Cholesterol oxidase 
(CHOD) method; 
Hitachi 717 analyser 
(Hitachi Instruments, 
California, USA). 
Measured after preci-
pitation of very-low density 
lipoprotein (VLDL) and 
low-density lipoprotein 
(LDL) by polyethylene 
glycol PEG 6000. 
Lipase/glycerol 
kinase method; 
Hong Kong 
Workforce 
Survey on CVD 
Risk Factors  
Venous 
Plasma 
Enzymatic method, 
with reagents (Baker 
Instruments 
Corporation, 
Allentown, PA 18103, 
USA) with Cobas Mira 
analyzer (Hoffman-La 
Roche and Co., Basle 
Switzerland).  
Enzymatic method after 
precipitation with dextran 
sulphate-MgCl2 on Cobas 
Mira analyzer (Hoffman-
La Roche and Co., Basle 
Switzerland) 
Enzymatic method, 
with reagents 
(Baker Instruments 
Corporation, 
Allentown, PA 
18103, USA) with 
Cobas Mira 
analyzer (Hoffman-
La Roche and Co., 
Basle Switzerland) 
Qingdao 
Diabetes Survey 
2002 
Venous 
Plasma 
Enzymatic method 
(AMS Analyzer 
Medical System, 
SABA-18, Rome, Italy)
Enzymatic method after 
precipitation (AMS 
Analyzer Medical System, 
SABA-18, Rome, Italy) 
Enzymatic method 
(AMS Analyzer 
Medical System, 
SABA-18, Rome, 
Italy) 
Qingdao 
Diabetes Study 
2006 
Serum Enzymatic method 
(Olympus reagent) 
With OLYMPUS-
AU640 Automatic 
Analyzers (Olympus 
Optical. Tokyo, Japan)
Direct method (Olympus 
reagent) with OLYMPUS-
AU640 Automatic 
Analyzers (Olympus 
Optical. Tokyo, Japan) 
Enzymatic method 
(Olympus reagent) 
with OLYMPUS-
AU640 Automatic 
Analyzers 
(Olympus Optical. 
Tokyo, Japan) 
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Finland     
East-West men Serum Enzymatic techniques 
(Monotest, Boehringer 
Mannheim GmbH, 
FRG) 
Olli C3000 photometer 
(Kone Oy, Finland) 
 
Enzymetic method after 
precipitation of VLDL 
and LDL by means of 
dextran-magnesium-
chloride, with Olli C3000 
photometer (Kone Oy, 
Finland) 
Enzymatic 
techniques 
(Monotest, 
Boehringer 
Mannheim GmbH, 
FRG) 
Olli C3000 
photometer (Kone 
Oy, Finland) 
National 
FINRISK Study 
87, 92 
Serum Enzymatic techniques 
(Cholesterol oxidase-
peroxidase-
amidopyrine, CHOD-
PAP, Boehringer-
Mannheim, 
Mannheim, Germany) 
Enzymatic method after 
dextran sulfate 
magnesium chloride 
precipitation of 
apolipoprotein B (apoB)-
containing lipoproteins 
Enzymatic 
techniques (CHOD-
PAP, Boehringer-
Mannheim, 
Mannheim, 
Germany) 
National 
FINRISK Study 
2002 
Serum Enzymatic method 
(CHOD-PAP; Thermo 
Elektron Oy, Finland);
 
Enzymatic method 
(CHOD-PAP; Thermo 
Elektron Oy, Finland) 
after precipitation by the 
PTA-precipitation method
Enzymatic 
techniques 
(Glycerol 
phosphate oxidase-
peroxidase-
amidopyrine, 
GPO-PAP; Thermo 
Elektron Oy) 
Oulu Study Serum Enzymatic method 
(CHOD-PAP, 
Boehringer Mannheim, 
Mannheim, Germany). 
 
Enzymatic CHOD-PAP 
method after precipitation 
of LDL and VLDL with a 
reagent containing 
phosphotungstic acid and 
MgCl2 (Boehringer 
Mannheim) 
Enzymatic method 
(CHOD-PAP, 
Boehringer 
Mannheim, 
Mannheim, 
Germany) 
Savitaipale 
Study 
Plasma Enzymatic colorimetric 
method (CHOD-PAP) 
Cobas Integra 400/700 
analyzer 
Enzymatic colorimetric 
method (CHOD-PAP) 
Cobas Integra 400/700 
analyzer 
Enzymatic 
colorimetric 
method (CHOD-
PAP) Cobas  
Integra 400/700 
analyzer 
Vantaa Study Serum Enzymatic techniques 
(Boehringer-
Mannheim) 
Enzymatic method after 
precipitation with 
polyethylenglycol 
Enzymatic 
techniques 
(Boehringer-
Mannheim) 
India     
Chennai 94 Serum Enzymatic method; 
Hitachi 704 
autoanalyser, using 
Boehringer Mannheim 
(Mannheim, Germany) 
reagents 
Phosphotungstate-
magnesium precipitation 
method. 
Hitachi 704 autoanalyser, 
using Boehringer 
Mannheim  
(Mannheim, Germany) 
reagents 
Enzymatic method. 
Hitachi 704 
autoanalyser, using 
Boehringer 
Mannheim 
(Mannheim, 
Germany) reagents 
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Chennai 97 Venous 
Plasma 
CHOD-PAP method 
(Boehringer 
Mannheim, Germany);
Corning Express Plus 
Auto Analyser 
(Corning, medfied, 
MA, USA) 
Phosphotungstic acid 
method after  
precipitation of LDL and 
chylomicrons  
(Boehringer Mannheim, 
Germany);  
Corning Express Plus 
Auto Analyser (Corning, 
medfied, MA, USA) 
GPO-PAP method 
(Boehringer 
Mannheim, 
Germany);  
Corning Express 
Plus Auto Analyser 
(Corning, medfied, 
MA, USA) 
CURES Serum CHOD-PAP method 
with Hitachi-912 
Autoanalyser (Hitachi, 
Mannheim, Germany) 
using kits supplied by 
Roche Diagnostics 
(Mannheim, 
Germany).  
 
Direct method 
(polyethylene glycol–
pretreated enzymes)  
with Hitachi-912 
Autoanalyser (Hitachi, 
Mannheim, Germany) 
using kits supplied by 
Roche Diagnostics 
(Mannheim, Germany).  
GPO-PAP method; 
Hitachi-912 
Autoanalyser 
(Hitachi, Mannheim, 
Germany) using 
kits supplied by 
Roche Diagnostics 
(Mannheim, 
Germany).  
Chennai 2006 Serum Standard enzymatic 
procedures  
(Roche Diagnostics, 
Mannheim, Germany) 
Direct assay method 
(Roche Diagnostics, 
Mannheim, Germany) 
Standard 
enzymatic 
procedures (Roche 
Diagnostics, 
Mannheim, 
Germany) 
Italy     
Cremona Study Plasma Enzymatic techniques 
(Boehringer-
Mannheim, 
Mannheim, Germany) 
with CIBA Corning 
550 Express Auto-
analyser  
Precipitation with PEG 
using a Colortest kit 
(Roche, Basel, 
Switzerland). 
Enzymatic 
techniques 
(Boehringer-
Mannheim, 
Mannheim, 
Germany) with 
CIBA Corning 550 
Express Auto-
analyser 
Japan     
Funagata Study Plasma Cholesterol oxidase 
method (L-type Wako 
CHO-H [Wako Pure 
Chemical Industries, 
Osaka, Japan])  
with TBA 80FR 
(Toshiba medical 
system corporation, 
Tokyo) 
Direct method 
(Cholesterol N HDL 
[Daiichi Pure Chemicals, 
Tokyo, Japan]) with TBA 
80FR (Toshiba medical 
system corporation, 
Tokyo) 
GPO HDAOS 
method (Pureauto 
S TG-N [Daiichi 
Pure Chemicals, 
Tokyo, Japan]) with 
TBA 80FR (Toshiba 
medical system 
corporation, Tokyo) 
Hisayama Study Serum Enzymatic techniques 
(TBA-80S; Toshiba 
Inc., Tokyo, Japan) 
Enzymatic method after 
precipitation of of VLDL 
and LDL with dextran 
sulfate and magnesium 
(TBA-80S; Toshiba Inc., 
Tokyo, Japan) 
Enzymatic 
techniques (TBA-
80S; Toshiba Inc., 
Tokyo, Japan) 
Mauritius     
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Mauritius 1987 Venous 
plasma 
Manual enzymatic 
colorimetric method 
(Coulter Minikem 
Spectrophotometer), 
(Boeringer Cat no 
701912) 
 
Manual enzymatic 
colorimetric method 
(Coulter Minikem 
Spectrophotometer), 
(Boeringer Cat no  
701912) 
Precipitation method 
(Biomerieux) 
Manual enzymatic 
colorimetric 
method(Coulter 
Minikem 
Spectrophotometer) 
(Boeringer Cat nr 
400971) 
Mauritius 1992 Venous 
plasma 
Automated enzymatic 
method with 
Chemistry Profile 
Analyser Model LS 
(Coulter- France) 
Automated enzymatic 
method, Chemistry 
Profile Analyser Model LS 
(Coulter- France) 
Precipitation method 
(Biomerieux) 
Automated 
enzymatic method 
with Chemistry 
Profile Analyser 
Model LS (Coulter- 
France) 
Mauritius 1998 Venous 
plasma 
Automated enzymatic 
methods; Cobas Mira 
analyzer (Roche 
Diagnostics, France) 
Automated enzymatic 
methods; Cobas Mira 
analyzer (Roche 
Diagnostics, France) 
Direct method 
(Biomerieux) 
Automated 
enzymatic 
methods; Cobas 
Mira analyzer 
(Roche Diagnostics, 
France) 
Poland     
POLMONICA Serum Direct Liebermann-
Burchard method 
(Boehringer-
Mannheim) 
Determined in the 
supernatant after 
precipitation with heparin 
manganese (Boehringer-
Mannheim) 
Enzymatic method 
(Boehringer-
Mannheim) 
 
Republic of 
Cyprus 
 
   
Nicosia Diabetes 
Study 
Whole Blood
Cobas Micra Plus 
Roche 
Cobas Micra Plus Roche Cobas Micra Plus 
Roche 
Spain     
The Guía Study Plasma Standard enzymatic 
methods 
(Boehringer-
Mannheim Hitachi 717 
autoanalyser, Tokyo, 
Japan) 
Phosphotungstate 
precipitation (Boehringer-
Mannheim Hitachi 717 
autoanalyser, Tokyo, 
Japan) 
Standard 
enzymatic methods 
(Boehringer-
Mannheim Hitachi 
717 autoanalyser, 
Tokyo, Japan) 
The Viva Study Plasma Enzymatic techniques 
(Boehringer-
Mannheim) 
Enzymatic techniques 
(Boehringer-Mannheim) 
Enzymatic 
techniques 
(Boehringer-
Mannheim) 
Sweden     
MONICA Serum Enzymatic techniques 
(Boehringer-
Mannheim GmbH, 
Germany) 
 
Phosphotungstate-Mg2+ 
precipitation method 
Enzymatic method 
(CHOD-PAP, 
Boehringer-
Mannheim GmbH, 
Germany) 
The Uppsala 
Longitudinal 
Study of Adult 
Serum Enzymatic techniques 
using IL Test 
Cholesterol Trinders's 
Separated by precipitation 
with magnesium 
chloride/ 
Enzymatic 
techniques using IL 
Test Cholesterol 
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Men (ULSAM) Method and IL Test 
Enzymatic-
colorimetric Method 
for use in a Monarch 
apparatus 
(Instrumentation 
Laboratories, 
Lexington, USA).  
(http://www.pubcare.
uu.se/ULSAM/invest/
70yrs/meth70.htm#09)
phosphotumgstate. Trinders's Method 
and IL Test 
Enzymatic-
colorimetric 
Method for use in a 
Monarch apparatus 
(Instrumentation 
Laboratories, 
Lexington, USA). 
The Netherlands     
The Hoorn 
Study 
Serum Enzymatic techniques 
(Boehringer-
Mannheim, 
Mannheim, Germany);
 
Enzymatic techniques 
after precipitation of the 
low and very low-density 
lipoproteins (Boehringer-
Mannheim, Mannheim, 
Germany) 
Enzymatic 
techniques 
(Boehringer-
Mannheim, 
Mannheim, 
Germany); 
Zutphen Serum Enzymatic techniques 
(CHOD-PAP mono-
test kit,Boehringer-
Mannheim) 
 
Enzymatic method after 
precipitation of apoB-
containing particles by 
means of dextran 
magnesium sulphate. 
Enzymatic 
techniques (CHOD-
PAP mono-test 
kit,Boehringer-
Mannheim) 
U.K.     
Isle of ELY 
Diabetes Project  
Plasma Enzymatic techniques, 
RA 1000 (Bayer 
Diagnostics, 
Basingstoke, Hants, 
UK) 
Enzymatic methods 
 
Standard 
automated 
enzymatic method 
with the RA1000 
(Bayer Diagnostics, 
Suffolk, U.K.), 
Newcastle Heart 
Project 
Plasma Cholesterol 
oxidase/peroxidase 
method with Cobas 
Bio centrifugal 
analyzer (Roche 
Products Ltd, Welwyn 
Garden City, UK) 
Measuring the 
supernatant cholesterol 
concentration after 
precipitation of apoB-
containing lipoproteins 
with heparin and 
manganese. 
Cobas Bio centrifugal 
analyzer (Roche Products 
Ltd, Welwyn Garden 
City, UK) 
Lipase/glycerol 
kinase method. 
Cobas Bio 
centrifugal 
analyzer (Roche 
Products Ltd, 
Welwyn Garden 
City, UK)  
 
The Goodinge 
Study 
Plasma Cholesterol esterase 
method (Boehringer 
Mannheim, Lewes, 
Sussex, U.K.) 
 
Enzymatic 
spectrophotometric 
method (Roche 
Diagnostics, Hatfield, 
Herts, U.K.) after 
precipitation of LDL by 
the addition of 
phosphotungstic acid in 
the presence of 
magnesium ions. 
Enzymatic 
spectrophotometric 
method (Roche 
Diagnostics, 
Hatfield, Herts, 
U.K.).  
 
Measures of lipid components in each study. 
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